<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33-vaccines-07-00195">
 <label>33.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jacobsen</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Rajendran</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Choi</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Sjursen</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Brokstad</surname>
    <given-names>K.A.</given-names>
   </name>
   <name>
    <surname>Cox</surname>
    <given-names>R.J.</given-names>
   </name>
   <name>
    <surname>Palese</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Krammer</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Nachbagauer</surname>
    <given-names>R.</given-names>
   </name>
  </person-group>
  <article-title>Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model</article-title>
  <source>mBio</source>
  <year>2017</year>
  <volume>8</volume>
  <pub-id pub-id-type="doi">10.1128/mBio.01463-17</pub-id>
 </element-citation>
</ref>
